PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberculosis Research

Executive Summary: PA-824 (CAS 187235-37-6) is a bicyclic nitroimidazole with robust bactericidal activity against both replicating and non-replicating Mycobacterium tuberculosis (Mtb) strains, including those resistant to first-line drugs (Ab Rahman et al., 2026). The primary mode of action involves inhibition of ketomycolate biosynthesis and enzymatic nitro-reduction leading to nitric oxide (NO) release within mycobacterial cells (doi:10.1038/s44321-026-00378-9). PA-824 demonstrates minimum inhibitory concentrations (MIC) of 0.015–0.25 μg/ml and an IC₅₀ < 2.8 μM under standardized in vitro conditions. The compound is insoluble in water and ethanol but dissolves at ≥17.85 mg/mL in DMSO, with optimal storage at -20°C for stability (APExBIO). Its validated performance and high purity (≥98%) support its utility in tuberculosis drug development and laboratory benchmarking.

Biological Rationale

Tuberculosis (TB) remains a global health threat, especially due to the rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains (Ab Rahman et al., 2026). Traditional antibiotics face declining efficacy, necessitating new agents with novel mechanisms. Nitroimidazole derivatives, such as PA-824, have emerged as promising candidates for overcoming resistance. PA-824 targets both actively replicating and dormant Mtb subpopulations, providing broad-spectrum antimycobacterial coverage (APExBIO). Its dual action on mycolic acid biosynthesis and cellular bioenergetics enables efficacy even in low-oxygen or nutrient-deprived environments, typical of latent TB infections.

Mechanism of Action of PA-824

PA-824, a bicyclic nitroimidazole, functions as a prodrug. Upon entry into Mtb cells, it undergoes enzymatic nitro-reduction, primarily via the bacterial deazaflavin-dependent nitroreductase (Ddn) pathway (doi:10.1038/s44321-026-00378-9). This reaction releases reactive nitrogen species, notably nitric oxide (NO), which disrupts the electron transport chain and impairs bacterial respiration. Simultaneously, PA-824 inhibits ketomycolate biosynthesis, blocking the production of essential mycolic acids for the mycobacterial cell wall (PA-824: Next-Generation Bicyclic Nitroimidazole). Dual targeting results in rapid bactericidal activity against both replicating and non-replicating Mtb. The inhibition of terminal oxidases (cytochrome bcc:aa3 and bd branches) further enhances bactericidal potency, especially when combined with agents like telacebec (Q203).

Evidence & Benchmarks

• PA-824 exhibits MIC values between 0.015–0.25 μg/ml against Mtb H37Rv strains in vitro at 37°C, pH 7.0 (Ab Rahman et al., 2026, DOI).
• IC₅₀ for Mtb growth inhibition is consistently <2.8 μM under aerobic conditions (Ab Rahman et al., 2026, DOI).
• PA-824 retains bactericidal activity against MDR and XDR Mtb clinical isolates (Stover et al., 2000, DOI).
• In murine models, PA-824 reduces Mtb lung CFU by 2–3 logs after 4 weeks of oral administration at 100 mg/kg (Singh et al., 2008, DOI).
• The compound demonstrates synergy with telacebec (Q203) in vitro, reducing resistance emergence (Ab Rahman et al., 2026, DOI).
• PA-824 is insoluble in water and ethanol but dissolves at ≥17.85 mg/ml in DMSO at room temperature (APExBIO).

Applications, Limits & Misconceptions

PA-824 is primarily used in laboratory and preclinical tuberculosis research. Its high purity and well-characterized mechanism make it suitable for: (1) cell viability and MIC assays; (2) drug synergy studies; (3) resistance modeling; and (4) mechanistic investigations of cell wall and respiratory inhibition (PA-824 (SKU A1736): Scenario-Driven Solutions). This article builds on these scenarios by providing atomic evidence and updated clinical context.
However, PA-824 is not approved for direct human therapeutic use and is unsuitable for infections outside the Mtb complex. Its activity depends on the presence of the Ddn nitroreductase pathway, limiting its application to organisms expressing this enzyme.

Common Pitfalls or Misconceptions

• PA-824 is not effective against non-mycobacterial pathogens lacking the Ddn pathway.
• It is not recommended for direct clinical use outside regulated research settings.
• Solubility issues arise if not dissolved in DMSO; aqueous or ethanol solvents are unsuitable.
• Long-term solution storage (>1 week at 4°C) may lead to compound degradation.
• Incorrect MIC determination may occur if testing against non-replicating forms without proper controls.

Workflow Integration & Parameters

For laboratory use, PA-824 should be reconstituted in DMSO to a concentration of at least 17.85 mg/mL, then diluted into assay buffers as required (APExBIO). Store the solid at -20°C and use prepared solutions immediately or within 1–2 days at 4°C. Quality documentation (COA, HPLC, NMR, MSDS) accompanies each lot, supporting reproducibility and compliance. Researchers should use standard Mtb H37Rv strains for benchmarking and report MIC/IC₅₀ values under defined conditions.

For more detailed integration protocols and troubleshooting, see PA-824 (SKU A1736): Addressing Key Challenges in Tuberculosis Research, which this article extends by providing updated synergy and mechanistic insights from 2026 studies.

Conclusion & Outlook

PA-824 stands out as a validated, high-purity research compound enabling the study of drug-resistant and latent tuberculosis mechanisms. Its dual-action mechanism—targeting both ketomycolate biosynthesis and respiratory chain disruption—makes it a cornerstone for rational drug regimen design. As new clinical evidence emerges, especially on combination therapies, PA-824 will remain a pivotal tool for TB research and drug development. For further reading on translational approaches and future directions, see PA-824 and the Next Frontier in Tuberculosis Research, which this article clarifies by distinguishing atomic mechanism-of-action evidence from broader translational strategies. For product specifications and ordering, refer to the PA-824 product page at APExBIO.